A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD

BACKGROUND: The combination of the inhaled muscarinic antagonist umeclidinium (UMEC) with the long-acting β(2)-agonist vilanterol (VI) has been shown to provide significant improvements in lung function compared with UMEC, VI, or placebo (PBO) in patients with chronic obstructive pulmonary disease (...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Int J Chron Obstruct Pulmon Dis
Autori principali: Siler, Thomas M, Donald, Alison C, O’Dell, Dianne, Church, Alison, Fahy, William A
Natura: Artigo
Lingua:Inglês
Pubblicazione: Dove Medical Press 2016
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4869636/
https://ncbi.nlm.nih.gov/pubmed/27274218
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S102962
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi